

Gene profile analysis of colorectal cancer cell lines by cDNA macroarray

NOBORU SAITO^{1,2}, SHINGO KAMEOKA¹ and RYUJI FURUKAWA³

Departments of ¹Surgery II, ²General Medicine, and ³Central Clinical Laboratories,
Tokyo Women's Medical University School of Medicine, Tokyo, Japan

Received December 1, 2006; Accepted January 24, 2007

Abstract. In order to identify high-risk groups of patients with cancer, understanding the mechanisms of invasion and metastasis from the viewpoint of gene expression is required; in particular, the changes in gene expression as tumours gain the ability to metastasise. Using a rat model of metastatic colorectal cancer (CRC), we determined the expression profiles of CRC cells that metastasised to the liver and the lung. In the hepatopulmonary metastasis model, metastasising ability increased with successive transplanted cell line generations. No significant differences in cellular proliferation ability were seen between the original cell line and succeeding metastatic cell lines. Analysis using cDNA macroarray showed that metastasising ability was associated with increased expression of integrin $\beta 4$, γ -catenin, Smad 7, Bax, Bcl-2, c-fos and TGF- α , and a particularly marked increased expression of TGF- β , PDGFb, Cdk4 and Rho B. Expression of both Rho GDIb and Gelsolin was reduced. These results suggest that high metastasising ability does not derive from a single gene, but rather through accumulated changes in the expression of several different genes.

Introduction

Under the banner of 'tailor-made medicine', we now expect diagnosis and treatment to be suited to the individual patient. The first stage is preparing a profile for each disease, because if we understand their genetic expression profiles we can then classify diseases on this basis. A disease cannot be identified from the expression profiles of one or two genes, but its characteristics can be elicited from the pattern of expression of hundreds or thousands of different genes.

Expression profiling using DNA chips (i.e. DNA microarrays) has attracted much interest in recent years, but for the present study we chose to use DNA macroarrays as the easier

method at present. We chose as the target disease group 'malignant tumours', because of their high prevalence and poor cure rates. Using a rat model of metastatic colorectal cancer (CRC) we investigated changes in gene expression as the tumours gained the ability to metastasise, in order to elucidate the mechanisms of invasion and metastasis from the gene expression standpoint.

Materials and methods

Establishment of a metastatic cell line. We developed a cell line with the ability to metastasise to the liver by repeatedly injecting a $2 \times 10^6/100\text{-}\mu\text{l}$ cell suspension of a rat CRC cell line (ACL-15) into the anterior mesenteric vein (a branch of the portal vein) of F344 rats, and then harvesting cells from the hepatic metastases. We confirmed the formation of pulmonary metastases after introduction of hepatic metastatic cells through the caudal vein, and we repeatedly harvested cells from the pulmonary metastases. Both procedures were repeated for four generations, establishing cell lines with the ability to metastasise to both the liver and lung.

Orthotopic transplant model. The cell lines with the ability to metastasise to both organs were orthotopically transplanted under the caecal serosa, and the animals were monitored for development of hepatic and pulmonary metastases, which were then sampled.

Monitoring of cellular proliferation. Formation of metastases became more active with each generation. We identified changes in cellular characteristics in order to determine if this was caused by increased cell proliferation or by changes in metastasising ability, such as cellular adhesiveness.

DNA macroarray. We extracted mRNA from cell lines undergoing the process of attaining the ability to metastasise, and compared the expression profiles of 434 genes using a cDNA macroarray, the Gene NavigatorTM cDNA array system (Toyobo Co. Ltd, Osaka, Japan). Initial total mRNA extraction was performed using the Isogen acid-guanidium-phenol-chloroform (AGPC) kit (Nippon Gene Co. Ltd, Toyama, Japan). Treatment with DNase digested any remnant strands of DNA. Finally, mRNA was retrieved using the MACS mRNA isolation kit (Daiichi Pure Chemical Co. Ltd, Tokyo, Japan).

Correspondence to: Dr Noboru Saito, Department of Surgery II, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
E-mail: nobosaito@surg2.twmu.ac.jp

Key words: cDNA macroarray, colorectal cancer, gene expression, profile analysis

Table I. Upregulated genes.

Gene	Class
Bax	Tumour suppressor gene/apoptosis
Bcl-2	Tumour suppressor gene/apoptosis
Bcl-X (Bcl- β)	Tumour suppressor gene/apoptosis
Cdk6 (PLSTIRE)	Cell cycle protein
Skp2 p45	Cell cycle protein
c-fos	Regulatory transcription factor
CBP (CREB-binding protein)	Regulatory transcription factor
TGF- α	Growth factor and hormone
HSC70	Signaling intermediates
TINP-2	Signaling intermediates
Ran	GDP/GTP binding proteins
Ran BP-1	GDP/GTP binding proteins
ARF1	GDP/GTP binding proteins
ARF5	GDP/GTP binding proteins
ARF6	GDP/GTP binding proteins
CD4	Lymphocyte signaling
γ -catenin (plakoglobin)	Cell adhesion protein
Integrin β 4	Cell adhesion protein
Smad7 (MADH7)	Regulatory transcription factor
GM2 activator protein	Other
AMF-R (autocin motility factor receptor)	Membrane receptor

Table II. Upregulated genes: high expression.

Gene	Class
TDAG 51	Tumour suppressor gene/apoptosis
Lamin A	Tumour suppressor gene/apoptosis
Cdk4 (PSK-13)	Cell cycle protein
Cdc37 homolog	Cell cycle protein
ER α (estrogen receptor α)	Steroid receptor
Erk1	Protein kinase
TGF- β	Growth factor and hormone
PDGF b	Growth factor and hormone
PI3 kinase p110 α	Signaling intermediates
Rho B	GDP/GTP binding proteins
Rho C	GDP/GTP binding proteins
GSTP1 (glutathion S-transferase P1)	Enzyme

Results

Development of a metastatic cell line. Through reimplantation of successive generations of cell lines that had acquired the ability to metastasise to the liver and the lung, a marked increase in metastasis formation was seen in rats transplanted with the fourth generation compared with the original cell line.

Table III. Downregulated genes.

Gene	Class
Rho GDI β	GDP/GTP binding proteins
Angiopoietin-1	Growth factor and hormone
Sin (Efs)	Signaling intermediate
Granzyme B	Tumour suppressor gene/apoptosis
Gelsolin	Tumour suppressor gene/apoptosis

Cellular proliferation. When we examined cell proliferation ability using [3 H]-thymidine uptake, no significant difference was seen between the original strain and daughter strains for metastasising ability. We therefore investigated changes in metastasising ability by determining gene expression profiles, thereby determining how the cellular characteristics had changed.

Gene expression profiles. Examination of the cDNA macroarray results for the original cell line and cell lines metastasising to the liver, the lung, or both, revealed increases and decreases in the expression of a variety of genes during the process of acquiring metastasising ability (Fig. 1).

First, compared with the original cell line, in the metastasising strains there was increased expression of 21 genes; in particular, regulatory cell adhesion proteins, including γ -catenin and integrin β 4; transcription factors such as Smad 7; and growth factors such as TGF- α (Table I).

Second, in the metastasising strains there was markedly increased expression of 12 genes: growth factors, including TGF- β and PDGFb; cell cycle proteins such as Cdk4 and Cdc37; and GDP/GTP binding proteins, including Rho B and Rho C (Table II).

Third, in the metastasising strains there was reduced expression of 5 genes, including tumour suppressor genes related to apoptosis, such as Granzyme B and Gelsolin (Table III).

Fourth, expression profiles were compared between groups to determine if quantitative analysis of differences in expression levels was possible with macroarrays, unlike with microarrays (Fig. 2). Marked changes were detected for 9 genes in the pulmonary metastatic cell line, with increased expression of 8 genes (TDAG 51, Lamin A, Cdk4, Cdc37 homolog, Erk1, PI3 kinase p110 α , Rho B, and Rho C), and decreased expression of 1 gene (Gelsolin), confirming the quantitative significance of this method.

Discussion

Cancer research in recent years has seen a variety of approaches to the elucidation of the clinical picture in cancer patients. In particular, the greatest clinical problem, the degree of malignancy, derives from a tumour's ability to metastasise. Because the initial stage of destruction of the basement membrane is an important part of the mechanism of cancer invasion and metastasis, previous studies have investigated the constituents of the extracellular matrix, including laminin, fibronectin and type IV collagen (1,2). In




Figure 1. Comparison of the original cell line (Ori), hepatic metastasis line (L4), pulmonary metastasis line (M4), and the cell line tending to metastasise to both the liver and lung (LM4). The darker the green, the higher the level of expression. Relative indices from 10 to 1000 are indicated by the three shades.




Figure 2. Comparison of the gene expression profiles of the two groups. Differences in the level of expression between the original cell line (Ori), injected into the rat colon, and the pulmonary metastasis cell line of hepatocellular origin (LM4) are shown as shades of green: the darker the green, the higher the level of expression. Relative indices from 10 to 1000 are indicated by the three shades.

clinical studies, laminin has been identified, by both serological and immunohistochemical approaches, as a significant predictive factor for the progression of CRC. However, clinical studies that have begun after metastases developed have failed to elucidate the mechanisms of acquiring metastasising ability, necessitating studies using basic metastatic models. Prior to the present study, we spent considerable time establishing such a model, and conducted basic studies of combination therapies with angiogenesis inhibitors on cellular adhesiveness (3). Further experimentation was required before we succeeded in developing a model that reproduced both hepatic and pulmonary metastases (this model will be described in detail elsewhere). Clinically, CRC in humans usually metastasises to the liver before the lung, although in some cases pulmonary metastases without hepatic metastases have occurred. Since this does not follow the usual pattern (i.e. that cancer cells travel from the lung parenchyma via the inferior vena cava to the lung), studies of metastasising ability at the cellular level have become necessary.

For the present gene profile study, rather than use a DNA chip (DNA microarray) (4-14), we chose a DNA macroarray for its superior ease of use and ability to make quantitative measurements (15-19). The former holds from several hundred to several tens of thousand dot-shaped mRNA measuring probes arranged on a 1 to 2-cm square plate, whereas the latter has a similar number of dot-shaped mRNA measuring probes, which, as the name suggests, are visible to the naked eye, arranged on a filter ~10x15 cm in size. DNA chip cluster analyses are generally graded as increased, unchanged or decreased, whereas macroarrays allow for a more detailed analysis of the level of expression, and are considered to provide better quantitative results than DNA chips. Production of expression profiles using DNA macroarrays does not require the expensive equipment needed for microarrays, and can be performed using standard equipment found in general laboratories (20-25). Although results obtained using macroarrays are superior from the quantitative point of view, often more genes can be analysed using DNA chips (26-30).

In this study, we identified nine mRNA genes with different levels of expression from only two different cell lines: the original cell line metastasising to the liver and a fourth-generation cell line metastasising to the lung. This level of variation in the expression profile between cell lines derived from the same source (i.e. CRC) (31-35) suggests that many different mRNA genes with different levels of expression will be found in studies of different diseases with different conditions. In our experience, it is difficult to identify different levels of gene expression in cancers at different stages, even in the same organ. Many mRNA genes show different levels of expression between hormone-dependent and -independent cancers, so different approaches can yield widely differing results (36,37).

We did not find a difference in the expression of 395 mRNA genes between cancer cells metastasising to the lung and to the liver, which left 39 genes as the subject of analyses. In other words, of 434 genes, 91% were 'undetected' and this result is meaningful in itself. We examined the original cell line, and the cell lines metastasising to the liver, the lung, and both the liver and lung, and quantitatively determined increases and decreases in the expression of several genes as

part of the process of acquiring metastasising ability. In future studies, we intend to concentrate on the 9 genes thus identified, with the aim of identifying mRNA specific to the lung or liver for possible clinical application as genetic markers and thus identification of high-risk groups of patients.

Acknowledgements

This study was supported in part by a Grant-in-Aid (no.16591357) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. We would also like to thank Dr Mark Preston for assistance with this manuscript.

References

1. Saito N and Kameoka S: Serum laminin is an independent prognostic factor in colorectal cancer. *Int J Colorectal Dis* 20: 238-244, 2005.
2. Saito N: The serological and histological study of laminin, as a predictive factor of liver metastasis of colon cancer (in Japanese). *J Jpn Soc Coloproctol* 44: 898-905, 1991.
3. Saito N, Mitsuhashi M, Hayashi T, *et al*: Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470. *Int J Clin Oncol* 6: 215-220, 2001.
4. Kim IJ, Kang HC, Jang SG, *et al*: Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. *Carcinogenesis* 27: 392-404, 2006.
5. Roberts ML, Drosopoulos KG, Vasileiou I, *et al*: Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. *Int J Cancer* 118: 616-627, 2006.
6. Watson NF, Madjd Z, Scrimgeour D, Spendlove I, Ellis IO, Scholefield JH and Durrant LG: Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. *World J Surg Oncol* 3: 47, 2005.
7. Korabiowska M, Cordon-Cardo C, Schinagl M, Karaus M, Stachura J, Schulz H and Fischer G: Loss of Ku70/Ku80 expression occurs more frequently in hereditary than in sporadic colorectal tumours: Tissue microarray study. *Hum Pathol* 37: 448-452, 2006.
8. Goethals L, Perneel C, Debucquoy A, *et al*: A new approach to the validation of tissue microarrays. *J Pathol* 208: 607-614, 2006.
9. Shiono S, Ishii G, Nagai K, *et al*: Immunohistochemical prognostic factors in resected colorectal lung metastases using tissue microarray analysis. *Eur J Surg Oncol* 32: 308-309, 2006.
10. van de Wiel MA, Costa JL, Smid K, *et al*: Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations. *Cancer Res* 65: 10208-10213, 2005.
11. Davison EJ, Tarpey PS, Fiegler H, Tomlinson IP and Carter NP: Deletion at chromosome band 20p12.1 in colorectal cancer revealed by high resolution array comparative genomic hybridization. *Genes Chromosomes Cancer* 44: 384-391, 2005.
12. Croner RS, Peters A, Brueckl WM, *et al*: Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. *Cancer* 104: 395-404, 2005.
13. Belluco C, Mammano E, Petricoin E, *et al*: Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. *Clin Chim Acta* 357: 180-183, 2005.
14. Wang JY, Yeh CS, Tzou WS, *et al*: Analysis of progressively overexpressed genes in tumourigenesis of colorectal cancers using cDNA microarray. *Oncol Rep* 14: 65-72, 2005.
15. Zhong WD, He HC, Bi XC, Ou RB, Jiang SA and Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. *Chin Med J* 119: 570-573, 2006.
16. Okahara S, Arimura Y, Yabana T, *et al*: Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis. *Aliment Pharmacol Ther* 21: 1091-1097, 2005.
17. Midorikawa T, Chikazawa T, Yoshino T, Takada K and Arase S: Different gene expression profile observed in dermal papilla cells related to androgenic alopecia by DNA macroarray analysis. *J Dermatol Sci* 36: 25-32, 2004.

18. Kurdi M, Cerutti C, Randon J, McGregor L and Bricca G: Macroarray analysis in the hypertrophic left ventricle of renin-dependent hypertensive rats: identification of target genes for renin. *J Renin-Angiotensin-Aldosterone Syst* 5: 72-78, 2004.
19. Brown M, Robinson C, Davies IM, Moffat CF, Redshaw J and Craft JA: Temporal changes in gene expression in the liver of male plaice (*Pleuronectes platessa*) in response to exposure to ethynyl oestradiol analysed by macroarray and real-time PCR. *Mutat Res* 552: 35-49, 2004.
20. Ohira T, Akutagawa S, Usuda J, *et al*: Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. *Oncol Rep* 9: 723-728, 2002.
21. Nakajima F, Nishimori H, Hata F, *et al*: Gene expression screening using a cDNA macroarray to clarify the mechanisms of peritoneal dissemination of pancreatic cancer. *Surg Today* 33: 190-195, 2003.
22. Yamagishi M, Higashikata T, Ishibashi-Ueda H, *et al*: Sustained upregulation of inflammatory chemokine and its receptor in aneurysmal and occlusive atherosclerotic disease: results from tissue analysis with cDNA macroarray and real-time reverse transcriptional polymerase chain reaction methods. *Circ J* 69: 1490-1495, 2005.
23. Sgarlato GD, Eastman CL and Sussman HH: Panel of genes transcriptionally up-regulated in squamous cell carcinoma of the cervix identified by representational difference analysis, confirmed by macroarray, and validated by real-time quantitative reverse transcription-PCR. *Clin Chem* 51: 27-34, 2005.
24. Usui T, Yamagami S, Yokoo S, Mimura T, Ono K and Amano S: Gene expression profile in corneal neovascularization identified by immunology related macroarray. *Mol Vision* 10: 832-836, 2004.
25. Minoshima H, Suyama E, Kawasaki H and Taira K: Cancer gene validation using ribozymes and macroarray. *Nucleic Acids Res Suppl* 3: 251-252, 2003.
26. Worst TJ, Freeman WM, Walker SJ and Vrana KE: Systematic screening of gene expression using a cDNA macroarray. *Method Mol Med* 79: 243-259, 2003.
27. Suyama E, Minoshima H, Kawasaki H and Taira K: Identification of AP-2-regulated genes by macroarray profiling of gene expression in human A375P melanoma. *Nucleic Acids Res Suppl* 2: 247-248, 2002.
28. De Fraipont F, Le Moigne G, Defaye G, *et al*: Transcription profiling of benign and malignant adrenal tumours by cDNA macroarray analysis. *Endocr Res* 28: 785-786, 2002.
29. Nomura H, Nishimori H, Yasoshima T, *et al*: A new liver metastatic and peritoneal dissemination model established from the same human pancreatic cancer cell line: analysis using cDNA macroarray. *Clin Exp Metastasis* 19: 391-399, 2002.
30. Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C and Kremsdorf D: Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. *Oncogene* 21: 2926-2937, 2002.
31. Augenlicht LH, Velcich A, Klampfer L, *et al*: Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. *J Nutr* 133: 2410-2416, 2003.
32. van Erk MJ, Krul CA, Caldenhoven E, Stierum RH, Peters WH, Woutersen RA and van Ommen B: Expression profiling of colon cancer cell lines and colon biopsies: towards a screening system for potential cancer-preventive compounds. *Eur J Cancer Prev* 14: 439-457, 2005.
33. Barrier A, Boelle PY, Lemoine A, *et al*: Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. *Dis Colon Rectum* 48: 2238-2248, 2005.
34. Barrier A, Lemoine A, Boelle PY, *et al*: Colon cancer prognosis prediction by gene expression profiling. *Oncogene* 24: 6155-6164, 2005.
35. Hao CY, Moore DH, Chiu YS, *et al*: Altered gene expression in normal colonic mucosa of individuals with polyps of the colon. *Dis Colon Rectum* 48: 2329-2335, 2005.
36. Nakeff A, Sahay N, Pisano M and Subramanian B: Painting with a molecular brush: genomic/proteomic interfacing to define the drug action profile of novel solid-tumour selective anticancer agents. *Cytometry* 47: 72-79, 2002.
37. Banerjee A, Feakins RM, Nickols CD, Phillips SM, Powar MP, Bustin SA and Dorudi S: Immunogenic hsp-70 is overexpressed in colorectal cancers with high-degree microsatellite instability. *Dis Colon Rectum* 48: 2322-2328, 2005.